Marius_logo_CMYK_no background.png
Marius Pharmaceuticals Announces Launch of ReThink Testosterone, Disease-State Awareness Initiative for Patients
July 24, 2023 09:00 ET | Marius Pharmaceuticals LLC
RALEIGH, N.C., July 24, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or Testosterone Deficiency, is proud to...
clarus_final_indentity.jpg
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)
May 18, 2022 09:05 ET | Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Clarus plans to list this patent...
clarus_final_indentity.jpg
Clarus Therapeutics Announces Closing of Upsized $30.0 Million Underwritten Public Offering
April 27, 2022 13:43 ET | Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., April 27, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
clarus_final_indentity.jpg
Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering
April 25, 2022 09:20 ET | Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by...
clarus_final_indentity.jpg
Clarus Therapeutics Announces Issuance of Two New Patents for JATENZO® (testosterone undecanoate)
November 30, 2021 09:05 ET | Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions Clarus plans to...
clarus_final_indentity.jpg
Clarus Therapeutics Announces Two Notices of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
October 26, 2021 09:05 ET | Clarus Therapeutics Holdings, Inc.
JATENZO® (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical...
Performer 8 Reviews
Performer 8 Reviews: Negative Side Effects or Real Benefits?
April 22, 2021 22:46 ET | Marketing By Kevin
New York, NY, April 22, 2021 (GLOBE NEWSWIRE) -- Unfortunately for men, performance issues in the bedroom can strike at any time. Age, anxiety, and physical health issues can all interfere with a...
clarus_final_indentity.jpg
Clarus Announces JATENZO® (Testosterone Undecanoate) Capsules, CIII Now Covered by Express Scripts
December 07, 2020 09:00 ET | Clarus Therapeutics, Inc.
JATENZO is the first and only FDA-approved oral testosterone replacement therapy of its kind Coverage effective December 1, 2020 on the Express Scripts National Preferred, Basic and High Performance...
clarus_final_indentity.jpg
CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO® (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE TREATMENT OF HYPOGONADISM
March 16, 2020 08:00 ET | Clarus Therapeutics, Inc.
Financing to speed commercialization of the only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., March 16, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics,...